Format

Send to

Choose Destination
Semin Cutan Med Surg. 2017 Mar;36(2 Suppl 2):S45-S48. doi: 10.12788/j.sder.2017.012.

Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment.

Author information

1
Rady Children's Hospital, San Diego, University of California, San Diego School of Medicine, San Diego, California, USA. leichenfield.rchsd@gmail.com.
2
Henry Ford Health System, Detroit, Michigan, USA.

Abstract

Several immunologic mediators-phosphodiesterase (PDE), interleukin (IL), small molecules, and Janus kinase-have been implicated in the pathogenesis of atopic dermatitis, and evidence has shown that blocking these mediators can help modify the disease process. Several new topical medications have been developed that target the enzyme PDE; crisaborole was recently approved by the US Food and Drug Administration (FDA) for the treatment of atopic dermatitis, and phase II studies have been completed on OPA-15406. The phase III clinical trial results of the systemic medication dupilumab, an inhibitor of the IL-4 receptor α subunit (which inhibits both IL-4 and IL-13 signaling), are currently being reviewed by the FDA.

KEYWORDS:

; OPA-15406; crisaborole; dupilumab; eczema; interleukin inhibition; phosphodiesterase-4 inhibition; topic dermatitis

PMID:
28654711
DOI:
10.12788/j.sder.2017.012
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center